Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort

BMJ Open

Volumn 3, Issue 7, 2013, Pages

  White, Douglas ^a   Pahau, Helen ^a   Duggan, Emily ^a   Paul, Sanjoy ^a   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; C REACTIVE PROTEIN; CORTICOSTEROID; FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY SCORE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EDUCATIONAL STATUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; OBSERVATIONAL STUDY; RHEUMATOID ARTHRITIS; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84883346434     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003083     Document Type: Article

References (40)

1. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73. (Pubitemid 29219206)
2. Boers M, Verhoeven AC, Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18. (Pubitemid 27351112)
3. Bakker MF, Jacobs JW, Welsing P.M., et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011; 70: 1099-103.
4. Machold KP, Stamm TA, Eberl G.J., et al. Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29: 2278-87. (Pubitemid 35266017)
5. Harrison MJ, Tricker KJ, Davies L, et al The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 2005; 32: 2330-6. (Pubitemid 41782233)
6. Manfredsdottir VF, Vikingsdottir T, Jonsson T., et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 734-40. (Pubitemid 43985343)
7. Kaltenhauser S, Pierer M, Arnold S., et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 100-4. (Pubitemid 44932795)
8. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68: 384-90.
9. Sanmarti R, Gomez-Centeno A, Ercilla G., et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007; 26: 1111-18. (Pubitemid 46863954)
10. Combe B, Cantagrel A, Goupille P. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 2003; 30: 2344-9. (Pubitemid 37413891)
11. Wagner E, Ammer K, Kolarz G., et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int 2007; 27: 1041-8. (Pubitemid 47248574)
12. Grigor C, Capell H, Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9. (Pubitemid 38942816)
13. Arnett FC, Edworthy SM, Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
14. O'Dell J.R., Haire CE, Erikson N, et al Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91. (Pubitemid 26138009)
15. Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009; 11:R51.
16. Van der Kooij SM, Allaart CF, Dijkmans B.A., et al. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 287-94. (Pubitemid 351483318)
17. Proudman SM, Keen HI, Stamp L.K., et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007; 37: 99-111. (Pubitemid 350198583)
18. Wells G, Becker JC, Teng J, et al Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
19. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220-30. (Pubitemid 30263609)
20. Lu CY, Williams KM, Day RO Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J 2007; 37: 601-6. (Pubitemid 47262898)
21. Van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012; 39: 1326-33.
22. Curtis JR, McVie T, Mikuls T.R., et al. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR trial. J Rheumatol 2013; 40: 572-8.
23. Sokka T, Toloza S, Cutolo M., et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009; 11:R7.
24. Saevarsdottir S, Wallin H, Seddighzadeh M., et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011; 70: 469-75.
25. Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? ERAS Study Group. Early Rheumatoid Arthritis Study. Ann Rheum Dis 2000; 59: 794-9.
26. Vliet Vlieland T.P., Buitenhuis NA, Van Zeben D, et al. Sociodemographic factors and the outcome of rheumatoid arthritis in young women. Ann Rheum Dis 1994; 53: 803-6.
27. Lopez-Bermejo A., Hernandez-Aguado I, Vera I.J., et al. Sex-specific, independent associations of insulin resistance with erythrocyte sedimentation rate in apparently healthy subjects. Thromb Haemost 2007; 97: 240-4. (Pubitemid 46592144)
28. Klaasen R, Wijbrandts CA, Gerlag D.M., et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011; 63: 359-64.
29. Bartoloni E, Alunno A, Luccioli F., et al. Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev Cardiovasc Ther 2010; 8: 1309-16.
30. Hannawi S, Haluska B, Marwick T.H., et al. Atherosclerotic disease is increased in recent onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007; 9:R116.
31. Chen YS, Yan W, Geczy C.L., et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R39.
32. Lindqvist E, Eberhardt K, Bendtzen K., et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 196-201. (Pubitemid 40193611)
33. Makinen H, Kautiainen H, Hannonen P., et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34: 316-21.
34. Hetland ML, Stengaard-Pedersen K, Junker P., et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69: 1789-95.
35. Geletka R, St Clair EW. Treatment of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 791-809.
36. Moreland LW, O'Dell JR, Paulus HE, et al A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64: 2824-35.
37. Smolen JS, Landewe R, Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
38. Claessen SJ, Hazes JM, Huisman M.A., et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009; 10: 71.
39. Kiely P, Walsh D, Williams R., et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity - the early RA network (ERAN). Rheumatology (Oxford) 2011; 50: 926-31.
40. Aletaha D, Neogi T, Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.